Recently the Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer Trial (APHINITY TRIAL) aimed to explore the effect of trastuzumab in association with pertuzumab, showing that the pertuzumab group had a lower percentage of heart failure compared to the trastuzumab/placebo group [108]. The gene discussed is ERBB2; the disease is breast cancer.